Press Releases

Investors

Press Releases

 
Press Releases
  Date Title and Summary View
Aug 3, 2017
Conference Call and Webcast Today at 4:30 p.m. EDT PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), today announced financial results for its fiscal 2017 third quarter ended June 30, 2017. The company is hosting a conference call at 4:30 p.m. EDT to discuss...
Jul 27, 2017
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on Thursday, August 3, 2017, at 4:30 p.m. EDT to discuss its financial results for the fiscal 2017 third quarter ended June 30, 2017. Conferen...
Jun 9, 2017
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on June 5, 2017, eleven new employees were awarded "inducement" grants of options under Rule 5635(c)(4) of the NASDAQ Marketplace Rules. The option...
May 3, 2017
- Conference Call and Webcast Today at 4:30 p.m. EDT PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), today announced financial results for its fiscal 2017 second quarter ended March 31, 2017. The company is hosting a conference call at 4:30 p.m. EDT to ...
Apr 26, 2017
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on Wednesday, May 3, 2017, at 4:30 p.m. EDT to discuss its financial results for the fiscal 2017 second quarter ended March 31, 2017. Conferen...
Apr 24, 2017
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) presented clinical data from a Phase 1a/1b study of ARC-AAT, the company's prior generation investigational medicine that was being studied for the treatment of liver disease associated with alpha-1 antitrypsin deficiency (AATD), at...
Apr 20, 2017
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented clinical data from a Phase 2 study of ARC-520 and a Phase 1/2 study of ARC-521, the company's prior generation investigational medicines that were being studied for the treatment of chronic hepatitis B virus (HBV) in...
Apr 5, 2017
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will present clinical data on ARC-520, ARC-521, and ARC-AAT, the company's prior generation investigational medicines that were being studied for the treatment of chronic hepatitis B infection and liver ...
Mar 23, 2017
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that on March 21, 2017 it entered into a stockholder rights agreement in accordance with an authorization and declaration from its board of directors of a dividend distribution of one preferred share purchase ...
Feb 6, 2017
- Conference Call and Webcast Today at 4:30 p.m. EST PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2017 first quarter ended December 31, 2016. The company is hosting a conference call at 4:30 p.m. EST to di...
Page:
1
... NextLast
= add release to Briefcase